Mutation abundance affects the therapeutic efficacy of EGFR-TKI in patients with advanced lung adenocarcinoma: A retrospective analysis

References

• Bai H, Wang Z, Chen K, Zhao J, Lee JJ, Wang S, Zhou Q, Zhuo M, Mao L, An T, et al. Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer. J Clin Oncol. 2012;30:3077–83. doi:10.1200/JCO.2011.39.3744. PMID:22826274.
   PubMed Web of Science ®Google Scholar
• Beltran H, Rickman DS, Park K, Chae SS, Sboner A, MacDonald TY, Wang Y, Sheikh KL, Terry S, Tagawa ST, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer discovery. 2011;1:487–95. doi:10.1158/2159-8290.CD-11-0130. PMID:22389870.
   PubMed Web of Science ®Google Scholar
• Chin TM, Quinlan MP, Singh A, Sequist LV, Lynch TJ, Haber DA, Sharma SV, Settleman J. Reduced Erlotinib sensitivity of epidermal growth factor receptor-mutant non-small cell lung cancer following cisplatin exposure: a cell culture model of second-line erlotinib treatment. Clin Cancer Res. 2008;14:6867–76. doi:10.1158/1078-0432.CCR-08-0093. PMID:18980981.
   PubMed Web of Science ®Google Scholar
• Cox JD, Scott CB, Byhardt RW, Emami B, Russell AH, Fu KK, Parliament MB, Komaki R, Gaspar LE. Addition of chemotherapy to radiation therapy alters failure patterns by cell type within non-small cell carcinoma of lung (NSCCL): analysis of radiation therapy oncology group (RTOG) trials. Int J Radiat Oncol Biol Phys. 1999;43:505–9. doi:10.1016/S0360-3016(98)00429-5. PMID:10078629.
   PubMed Web of Science ®Google Scholar
• Dang RK, Anthony RS, Craig JI, Leonard RC, Parker AC. Limitations of the use of single base changes in the p53 gene to detect minimal residual disease of breast cancer. Mol Pathol. 2002;55:177–81. doi:10.1136/mp.55.3.177. PMID:12032228.
   PubMedGoogle Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47. doi:10.1016/j.ejca.2008.10.026. PMID:19097774.
   PubMed Web of Science ®Google Scholar
• Ellison G, Donald E, McWalter G, Knight L, Fletcher L, Sherwood J, Cantarini M, Orr M, Speake G. A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samples. J Exp Clin Cancer Res. 2010;29:132. doi:10.1186/1756-9966-29-132.
   PubMed Web of Science ®Google Scholar
• Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Chu DT, Saijo N et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J ClinOncol. 2011;29:2866–74. doi:10.1200/JCO.2010.33.4235. PMID:21670455.
   PubMed Web of Science ®Google Scholar
• Gazdar AF, Minna JD. Inhibition of EGFR signaling: all mutations are not created equal. PLoS medicine. 2005;2:e377. doi:10.1371/journal.pmed.0020377. PMID:16288556.
   PubMed Web of Science ®Google Scholar
• Han JY, Park K, Kim SW, Lee DH, Kim HY, Kim HT, Ahn MJ, Yun T, Ahn JS, Suh C et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol. 2012;30:1122–8. doi:10.1200/JCO.2011.36.8456. PMID:22370314.
   PubMed Web of Science ®Google Scholar
• Igawa S, Kasajima M, Ishihara M, Kimura M, Hiyoshi Y, Asakuma M, Otani S, Katono K, Sasaki J, Masuda N. Comparison of the efficacy of gefitinib in patients with non-small cell lung cancer according to the type of epidermal growth factor receptor mutation. Oncology. 2014;87:215–23. doi:10.1159/000362603. PMID:25034225.
   PubMed Web of Science ®Google Scholar
• Jackman DM, Miller VA, Cioffredi LA, Yeap BY, Janne PA, Riely GJ, Ruiz MG, Giaccone G, Sequist LV, Johnson BE. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res. 2009;15:5267–73. doi:10.1158/1078-0432.CCR-09-0888. PMID:19671843.
   PubMed Web of Science ®Google Scholar
• Jackman DM, Yeap BY, Sequist LV, Lindeman N, Holmes AJ, Joshi VA, Bell DW, Huberman MS, Halmos B, Rabin MS et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res. 2006;12:3908–14. doi:10.1158/1078-0432.CCR-06-0462. PMID:16818686.
   PubMed Web of Science ®Google Scholar
• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90. PMID:21296855.
   PubMed Web of Science ®Google Scholar
• Jiang J, Wang C, Yu X, Sheng D, Zuo C, Ren M, Wu Y, Shen J, Jin M, Xu S. PCR-sequencing is a complementary method to amplification refractory mutation system for EGFR gene mutation analysis in FFPE samples. Exp Mol Pathol. 2015;99:581–9. doi:10.1016/j.yexmp.2015.10.002. PMID:26477713.
   PubMed Web of Science ®Google Scholar
• Kimura H, Fujiwara Y, Sone T, Kunitoh H, Tamura T, Kasahara K, Nishio K. High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non-small cell lung cancer patients. Cancer Sci. 2006;97:642–8. doi:10.1111/j.1349-7006.2006.00216.x. PMID:16827805.
   PubMed Web of Science ®Google Scholar
• Lee CK, Wu YL, Ding PN, Lord SJ, Inoue A, Zhou C, Mitsudomi T, Rosell R, Pavlakis N, Links M et al. Impact of Specific Epidermal Growth Factor Receptor (EGFR) mutations and clinical characteristics on outcomes after treatment With EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR-Mutant lung cancer: A meta-analysis. J Clin Oncol. 2015;33:1958–65. doi:10.1200/JCO.2014.58.1736. PMID:25897154.
   PubMed Web of Science ®Google Scholar
• Liang Y, Ma R. Comparison of therapeutic efficacy of gefitinib as first – and second- line therapies for patients with EGFR mutated advanced non – small cell lung cancer. J. 2014;22:2091–4.
   Google Scholar
• Linardou H, Dahabreh IJ, Bafaloukos D, Kosmidis P, Murray S. Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. Nat Rev Clin Oncol. 2009;6:352–66. doi:10.1038/nrclinonc.2009.62. PMID:19483740.
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129–39. doi:10.1056/NEJMoa040938. PMID:15118073.
   PubMed Web of Science ®Google Scholar
• Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362:2380–8. doi:10.1056/NEJMoa0909530. PMID:20573926.
   PubMed Web of Science ®Google Scholar
• Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11:121–8. doi:10.1016/S1470-2045(09)70364-X. PMID:20022809.
   PubMed Web of Science ®Google Scholar
• Mok T, Yang JJ, Lam KC. Treating patients with EGFR-sensitizing mutations: first line or second line–is there a difference? J Clin Oncol. 2013;31:1081–8. doi:10.1200/JCO.2012.43.0652. PMID:23401448.
   PubMed Web of Science ®Google Scholar
• Morita S, Okamoto I, Kobayashi K, Yamazaki K, Asahina H, Inoue A, Hagiwara K, Sunaga N, Yanagitani N, Hida T et al. Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations. Clin Cancer Res. 2009;15:4493–8. doi:10.1158/1078-0432.CCR-09-0391. PMID:19531624.
   PubMed Web of Science ®Google Scholar
• Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497–500. doi:10.1126/science.1099314. PMID:15118125.
   PubMed Web of Science ®Google Scholar
• Riely GJ, Pao W, Pham D, Li AR, Rizvi N, Venkatraman ES, Zakowski MF, Kris MG, Ladanyi M, Miller VA. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res. 2006;12:839–44. doi:10.1158/1078-0432.CCR-05-1846. PMID:16467097.
   PubMed Web of Science ®Google Scholar
• Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361:958–67. doi:10.1056/NEJMoa0904554. PMID:19692684.
   PubMed Web of Science ®Google Scholar
• Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science. 2004;305:1163–7. doi:10.1126/science.1101637. PMID:15284455.
   PubMed Web of Science ®Google Scholar
• Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T et al. osimertinib in untreated egfr-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378:113–25. doi:10.1056/NEJMoa1713137. PMID:29151359.
   PubMed Web of Science ®Google Scholar
• Won YW, Han JY, Lee GK, Park SY, Lim KY, Yoon KA, Yun T, Kim HT, Lee JS. Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations. J. Clin. Pathol. 2011;64:947–52. doi:10.1136/jclinpath-2011-200169. PMID:21725039.
   PubMed Web of Science ®Google Scholar
• Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, Zhou C, Hu CP, O'Byrne K, Feng J et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015;16:141–51. doi:10.1016/S1470-2045(14)71173-8. PMID:25589191.
   PubMed Web of Science ®Google Scholar
• Yang X, Zhuo M, Ye X, Bai H, Wang Z, Sun Y, Zhao J, An T, Duan J, Wu M et al. Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer. Oncotarget. 7;2016:20810–24. PMID:26989078.
   PubMedGoogle Scholar
• Zhao ZR, Wang JF, Lin YB, Wang F, Fu S, Zhang SL, Su XD, Jiang L, Zhang YG, Shao JY et al. Mutation abundance affects the efficacy of EGFR tyrosine kinase inhibitor readministration in non-small-cell lung cancer with acquired resistance. Med. Oncol. 2014;31:810. doi:10.1007/s12032-013-0810-6. PMID:24338271.
   PubMed Web of Science ®Google Scholar
• Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011a;12:735–42. doi:10.1016/S1470-2045(11)70184-X.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Zhang XC, Chen ZH, Yin XL, Yang JJ, Xu CR, Yan HH, Chen HJ, Su J, Zhong WZ et al. Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer. J Clin Oncol. 2011b;29:3316–21. doi:10.1200/JCO.2010.33.3757.
   PubMed Web of Science ®Google Scholar